CNS Pharmaceuticals Inc. Announces 1-for-12 Reverse Stock Split Effective July 22
TL;DR
CNS Pharmaceuticals' reverse stock split could streamline its capital structure, potentially making its stock more attractive to institutional investors and improving market perception.
CNS Pharmaceuticals will execute a 1-for-12 reverse stock split on July 22, 2025, adjusting warrants and equity awards proportionally, with cash in lieu of fractional shares.
CNS Pharmaceuticals' focus on developing treatments for brain and CNS cancers represents a hopeful advance against some of the most challenging diseases affecting humanity.
Discover how CNS Pharmaceuticals is tackling brain cancer with Berubicin, a novel drug that crosses the blood-brain barrier, a rare feat in oncology.
Found this article helpful?
Share it with your network and spread the knowledge!
CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company dedicated to developing treatments for brain and central nervous system cancers, has announced a 1-for-12 reverse stock split set to take effect on July 22, 2025. This strategic move will see every twelve shares of the company's common stock converted into one share, with corresponding adjustments made to warrants and equity awards to maintain proportionality. The company's stock will continue to trade under the symbol CNSP but will be assigned a new CUSIP number: 18978H508.
The reverse stock split is designed to uniformly affect all shareholders, with no fractional shares being issued. Instead, shareholders who would otherwise receive fractional shares will be compensated in cash. Additionally, the authorized share count of the company will be reduced to 25 million shares, while the par value per share will remain unchanged at $0.001. This decision reflects CNS Pharmaceuticals' commitment to optimizing its capital structure and enhancing shareholder value.
CNS Pharmaceuticals is at the forefront of developing innovative treatments for aggressive and currently incurable forms of brain cancer, such as glioblastoma multiforme (GBM). The company's lead drug candidate, Berubicin, represents a significant advancement in oncology as the first anthracycline believed to cross the blood-brain barrier, offering hope for patients with serious brain and CNS oncology indications.
For further details on the reverse stock split and CNS Pharmaceuticals' pioneering work in cancer treatment, interested parties can view the full press release here. More information about CNS Pharmaceuticals and its groundbreaking research can be found on the company's website at https://www.CNSPharma.com.
Curated from InvestorBrandNetwork (IBN)
